Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.IMVT · Entity 3632 | Director | August 28, 2026 | August 28, 2026 |
| Sio Gene Therapies Inc.SIOX · Entity 130622 | Director | April 15, 2021 | April 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date August 28, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,731 |
Ending reported balance
After 2026-08-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-28 · Exercise / conversion · Acquired 1,500 · Balance 118,231 F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Row 2 · 2026-08-28 · Sale · Disposed 1,500 · Balance 116,731 F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-11-19 | Direct | 65,181 |
Reported balance
After 2026-08-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-28 · Exercise / conversion · Disposed 1,500 · Balance 65,181 F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. F2: Reflects an award of stock options to purchase Common Shares that is fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 20,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
F2: Reflects an award of stock options to purchase Common Shares that is fully vested.
Sio Gene Therapies Inc.
Report date April 15, 2021 · Filed April 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2031-04-14 | Direct | 42,000 |
Reported balance
After 2021-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-15 · Grant · Acquired 42,000 · Balance 42,000 F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Karuna Therapeutics, Inc.
Report date March 18, 2024 · Filed March 18, 2024
Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 1
1 source rowRow 1 · 2024-03-18 · Disposition to issuer · Disposed 990 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.59 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-18 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.01 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-18 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.96 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-18 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.70 · Expires 2033-06-19 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-18 · Disposition to issuer · Disposed 1,904 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.
F4: These Options are fully vested.
F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Aug 28, 2026 16:27 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001764013-26-000103 · wk-form4_1787948868.xml · derivative · entry 4 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,181 Underlying: Common Stock · 1,500 shares Expires 2029-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 16:27 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,500 | $43.27 | $64,905.00 |
DisclosureSEC source: 0001764013-26-000103 · wk-form4_1787948868.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,731 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 16:27 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCommon Stock | 1,500 | $8.43 | $12,645.00 |
DisclosureSEC source: 0001764013-26-000103 · wk-form4_1787948868.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Read SEC document |
| July 24, 2026 Filed Jul 24, 2026 21:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001643071-26-000007 · wk-form4_1784930349.xml · derivative · entry 4 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,681 Underlying: Common Stock · 1,500 shares Expires 2029-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| July 24, 2026 Filed Jul 24, 2026 21:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,500 | $39.80 | $59,700.00 |
DisclosureSEC source: 0001643071-26-000007 · wk-form4_1784930349.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,731 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Read SEC document |
| July 24, 2026 Filed Jul 24, 2026 21:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCommon Stock | 1,500 | $8.43 | $12,645.00 |
DisclosureSEC source: 0001643071-26-000007 · wk-form4_1784930349.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:43 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001764013-26-000071 · wk-form4_1782517401.xml · derivative · entry 4 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,181 Underlying: Common Stock · 1,500 shares Expires 2029-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:43 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,500 | $38.01 | $57,015.00 |
DisclosureSEC source: 0001764013-26-000071 · wk-form4_1782517401.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,731 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:43 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCommon Stock | 1,500 | $8.43 | $12,645.00 |
DisclosureSEC source: 0001764013-26-000071 · wk-form4_1782517401.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001764013-26-000069 · wk-form4_1781640191.xml · derivative · entry 4 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,681 Underlying: Common Stock · 1,500 shares Expires 2029-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. F3 · balance_after: The Form 4 filed on May 20, 2026 inadvertently disclosed the total of all remaining options held by the Reporting Person following the reported transaction in this specific option. This total correctly reflects only the remaining options for the specific option. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,500 | $34.02 | $51,030.00 |
DisclosureSEC source: 0001764013-26-000069 · wk-form4_1781640191.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,731 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCommon Stock | 1,500 | $8.43 | $12,645.00 |
DisclosureSEC source: 0001764013-26-000069 · wk-form4_1781640191.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Read SEC document |
| May 20, 2026 Filed May 21, 2026 01:22 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001643071-26-000004 · wk-form4_1779326521.xml · derivative · entry 4 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 270,252 Underlying: Common Stock · 6,000 shares Expires 2029-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| May 20, 2026 Filed May 21, 2026 01:22 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 6,000 | $32.00 | $192,000.00 |
DisclosureSEC source: 0001643071-26-000004 · wk-form4_1779326521.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,731 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Read SEC document |
| May 20, 2026 Filed May 21, 2026 01:22 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCommon Stock | 6,000 | $8.43 | $50,580.00 |
DisclosureSEC source: 0001643071-26-000004 · wk-form4_1779326521.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:25 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 7,061 | $0.00 Strike: $24.61 | $0.00 |
DisclosureSEC source: 0001764013-26-000046 · wk-form4_1775766313.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,061 Underlying: Common Stock · 7,061 shares Expires 2036-04-07 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:25 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 13,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-26-000046 · wk-form4_1775766313.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,731 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:44 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 7,600 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000047 · wk-form4_1743713068.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:44 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 16,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000047 · wk-form4_1743713068.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,851 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:22 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 7,750 | $28.54 | $221,185.00 |
DisclosureSEC source: 0001764013-24-000200 · wk-form4_1733347352.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,663 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.03 - $29.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:46 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 4,690 | $0.00 Strike: $30.78 | $0.00 |
DisclosureSEC source: 0001764013-24-000061 · wk-form4_1712263559.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,690 Underlying: Common Stock · 4,690 shares Expires 2034-04-02 F2 · derivative.exercise_date: The shares underlying the options will vest on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:46 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 11,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000061 · wk-form4_1712263559.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,413 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 20:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Disposition to issuerOption (right to buy) · Derivative | 1,904 | $92.30 Strike: $237.70 | $175,739.20 |
DisclosureSEC source: 0001140361-24-013932 · form4.xml · derivative · entry 5 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,904 shares Expires 2033-06-19 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5 · derivative.exercise_date: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 20:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Disposition to issuerOption (right to buy) · Derivative | 5,000 | $227.04 Strike: $102.96 | $1,135,200.00 |
DisclosureSEC source: 0001140361-24-013932 · form4.xml · derivative · entry 4 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2032-06-14 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 20:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Disposition to issuerOption (right to buy) · Derivative | 8,500 | $201.99 Strike: $128.01 | $1,716,915.00 |
DisclosureSEC source: 0001140361-24-013932 · form4.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2031-06-15 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 20:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Disposition to issuerOption (right to buy) · Derivative | 12,500 | $232.41 Strike: $97.59 | $2,905,125.00 |
DisclosureSEC source: 0001140361-24-013932 · form4.xml · derivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2030-06-04 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 20:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Disposition to issuerCommon Stock | 990 | $330.00 | $326,700.00 |
DisclosureSEC source: 0001140361-24-013932 · form4.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2 · kind: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. F2 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. F2 · price: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:28 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,847 | $40.46 | $196,109.62 |
DisclosureSEC source: 0001764013-23-000155 · wk-form4_1701811692.xml · nonDerivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,158 F1 · security: Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person. F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.23 - $40.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:28 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,374 | $39.82 | $134,352.68 |
DisclosureSEC source: 0001764013-23-000155 · wk-form4_1701811692.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,005 F1 · security: Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.21 - $40.17 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:28 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,129 | $38.80 | $160,205.20 |
DisclosureSEC source: 0001764013-23-000155 · wk-form4_1701811692.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,379 F1 · security: Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.20 - $39.17 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:09 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantOption (right to buy) · Derivative | 1,904 | $0.00 Strike: $237.70 | $0.00 |
DisclosureSEC source: 0000950170-23-029403 · ownership.xml · derivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,904 Underlying: Common Stock · 1,904 shares Expires 2033-06-19 F2 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:09 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantCommon Stock | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-029403 · ownership.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 990 F1 · shares: Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:37 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 16,260 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001764013-23-000047 · wf-form4_168150462958764.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,260 Underlying: Common Stock · 16,260 shares Expires 2033-04-12 F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on April 12, 2024, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:37 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 12,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-23-000047 · wf-form4_168150462958764.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,508 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest in their entirety one year after the date of grant on April 12, 2024, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:27 UTC | Immunovant, Inc. IMVT · Entity 3632 | PurchaseCommon Stock | 15,000 | $5.60 | $84,000.00 |
DisclosureSEC source: 0001764013-22-000126 · wf-form4_166491518472332.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 20,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.59 - $5.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: These shares are owned by a trust (the "Trust"). Certain members of the Reporting Person's immediate family are beneficiaries of the Trust. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:46 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 31,668 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001764013-22-000095 · wf-form4_166094195240810.xml · derivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,668 Underlying: Common Stock · 31,668 shares Expires 2032-08-17 F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on August 17, 2023, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:46 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 21,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000095 · wf-form4_166094195240810.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,985 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest in their entirety one year after the date of grant on August 17, 2023, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:39 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $102.96 | $0.00 |
DisclosureSEC source: 0001593968-22-001149 · primary_01.xml · derivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 15, 2023, and (ii) the 2023 annual meeting of the Issuer's stockholders. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:08 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000362 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:08 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $110.80 | $277,000.00 |
DisclosureSEC source: 0001593968-22-000362 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:08 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-22-000362 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:56 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 71,492 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001764013-22-000015 · wf-form4_164202456711747.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,973 Underlying: Common Stock · 71,492 shares Expires 2032-01-10 F4 · derivative.exercise_date: Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:56 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 21,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000015 · wf-form4_164202456711747.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,926 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 00:05 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000017 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 00:05 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $130.44 | $326,100.00 |
DisclosureSEC source: 0001593968-22-000017 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 00:05 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-22-000017 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 22:21 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-002517 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 22:21 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $127.73 | $319,325.00 |
DisclosureSEC source: 0001593968-21-002517 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 22:21 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-002517 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:14 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-002355 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.